Biocon Biologic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biocon enters US ophthalmology market with US FDA approval of Yesafili

The fund plans to provide a $150 million mezzanine debt facility at 18-20% and arrange another $300 million from other lenders to finance the acquisition, said a person in the know. "The funding cost could vary by the instrument where the blend-in cost could be 14-15%," he added.

Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.

The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocons stake dilution in Bicara Therapeutics.

Adalimumab BS for subcutaneous injection is a biosimilar of Humira, offering therapeutic solutions for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease and ulcerative colitis